Mithra Signs Exclusive License and Supply Agreement with Adcock Ingram for Commercialization of Estelle® in Southern Africa

  • Mithra is eligible for a downpayment of EUR 1.5 million
  • 20-year exclusive license and supply agreement to generate annual recurring revenues and royalty payments
  • Production at the Mithra CDMO facility
  • Deal forms part of Mithra’s strategy to realise the full potential of the pipeline programs through global partnerships with leaders in Women’s Health

Liège, Belgium, 30 October 2018 – Mithra (Euronext Brussels: MITRA) today announced that it has entered into an exclusive license and supply agreement with Adcock Ingram to commercialize Estelle®, a combined oral contraceptive (COC), containing 15 mg Estetrol (E4) / 3 mg drospirenone (DRSP), in Southern Africa1. The product is a novel combined oral contraceptive with natural, native estrogen acting selectively in tissues combined with DRSP’s non-contraceptive benefits.

2018 Update and 2019 Outlook Given at the CPHI Conference

  • Estelle® Oral Contraception programme on track – US/CANADA Phase III arm due to complete in Q4 2018; partnering discussions ongoing including for us market
  • Preparations for Phase III Donesta® trials moving ahead, including co-partnering discussions
  • Further Marketing authorisations obtained for MyRing™

Liège, Belgium, 10 October 2018 – 20:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, provided an update on its key programmes at the CPHI world conference.

Notice of 2018 Extraordinary General Meeting Regarding Proposed Warrant Plan

Liège, Belgium, 5 October 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces its intention to hold an Extraordinary General Meeting (“EGM”) on the 5 November 2018 at 11:00 am in Flémalle, 57 rue de l’Expansion (Belgium). The meeting will consider a new warrant plan whereby a maximum of 1,881,974 warrants would be issued, subject to shareholder approval.

 

Presentation of Donesta® PhIIb Results at the 2018 Annual Meeting of the North American Menopause Society

Liège, Belgium, October 3nd 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces its Phase IIb results for Donesta® will be presented at the 29th Annual Meeting of the North American Menopause Society (NAMS), being held on 3-6 October 2018 in San Diego, CA.